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Background: Oocyte and embryo cryopreservation, using controlled ovarian stimulation 
(COS), are common fertility preservation methodologies in breast cancer patients receiving 
gonadotoxic neo (adjuvant) chemotherapy (CT). The effects of COS and peak estradiol levels 
on CT-induced side effects are unknown.
Patients and methods: Eighteen patients with stage II and III breast cancer underwent oocyte 
or embryo cryopreservation at Leiden University Medical Center before receiving docetaxel, 
adriamycin, and cyclophosphamide (TAC) CT (COS group). A control group (N=18) was ret-
rospectively selected from breast cancer patients, aged between 18 and 40, who underwent TAC 
CT without fertility preservation. CT -induced toxicity in the 2 groups was compared using χ2 
analysis. Associations between peak estradiol levels and distinct stimulation protocols and side 
effects in the COS group were investigated by using regression analysis.
Results: Patient characteristics between both groups were similar, except for a lower age in 
the COS group vs the control group (30.5 vs 35.2 years, P=0.005). No differences were seen in 
grade III/IV side effects between both groups. In the COS group, an increase in thrombopenia 
grade I/II was seen, while grade I/II stomatitis and constipation were significantly lower in the 
COS group as compared with the control group (P=0.006 and P=0.008, respectively). In the 
COS group, no association was found between the peak estradiol levels and distinct stimulation 
protocols and side effects of CT.
Conclusion: COS prior to TAC CT was not associated with an increase in grade III/IV side 
effects. Interestingly, COS may have a protective effect on mucositis and constipation. More-
over, the peak estradiol levels and distinct stimulation protocols had no effect on grade III/IV 
side effects in our study.
Keywords: chemotherapy, toxicity, fertility preservation, controlled ovarian hyperstimulation
Introduction
Premenopausal breast cancer patients who receive chemotherapy (CT) have a risk of 
decreased ovarian reserve, premature ovarian failure, and infertility after treatment.1–3 
Therefore, discussion of and referral for fertility preservation in patients who wish to 
have a child in the future is an essential part of the treatment plan.4–7 As mortality rates 
have declined over time in this patient group and patients often postpone their first preg-
nancy,2,8 oocyte and embryo cryopreservation are commonly used fertility preservation 
options.9 Both approaches require controlled ovarian stimulation (COS) for ~2 weeks. 
Conventional ovarian stimulation protocols cause high serum levels of estradiol.10,11 To 
block or to decrease estradiol during COS, new protocols with tamoxifen and aromatase 
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inhibitors in combination with low levels of follicle-stimulating 
hormone (FSH) are developed.10,12 Studies have shown that 
COS for fertility preservation with tamoxifen or aromatase 
inhibitors in patients with breast cancer are unlikely to increase 
recurrence risk.13–16 The effects of COS and the additional hor-
monal alterations on toxicity of CT have not been studied. Pre-
clinical evidence shows that sex hormones may interfere with 
side effects of CT.17,18 Therefore, we conducted a retrospective 
case–control study of the effects of COS on CT-induced toxicity 
in early breast cancer patients undergoing oocyte and embryo 
cryopreservation for fertility preservation prior to neo (adju-
vant) docetaxel, adriamycin, and cyclophosphamide (TAC) CT.
Patients and methods
Study population
Eligible patients with early breast cancer stage, Ic, II and 
III, and underwent oocyte or embryo cryopreservation at 
the gynecology department of the Leiden University Medi-
cal Center (LUMC) between 2009 and 2015. All patients 
received TAC CT (docetaxel 75 mg/m2 IV, adriamycin 50 
mg/m2 IV, and cyclophosphamide 500 mg/m2 IV, day 1, q3 
weeks) and were treated in 6 hospitals in the Netherlands. The 
control group was selected from all patients in the LUMC 
who underwent TAC CT between 2009 and 2015 without 
oocyte or embryo cryopreservation and with the age at 
diagnosis between 18 and 40 years. The retrospective study 
was conducted according with the Declaration of Helsinki 
and the Dutch “Code of Good Conduct,” and was approved 
by the Ethics Committee of the LUMC. Patient consent was 
assumed as per the no-objection rule of the “Code of Good 
Conduct” (https://www.federa.org/codes-conduct).
Stimulation protocols
The following stimulation protocols were used: 1) COS 
protocol with FSH, tamoxifen, and gonadotropin-releasing 
hormone (GnRH) antagonist; 2) protocol with FSH and a 
GnRH antagonist alone; and 3) protocol with FSH and a 
GnRH agonist. Patient received the distinct COS protocols 
depending on hormone receptor status of the tumor and tim-
ing of start in the follicular or luteal phase of the menstrual 
cycle. Typically, patients received COS on the second or third 
day of the menstrual bleeding with an average dose of 150 
U of FSH subcutaneously with or without 60 mg tamoxifen 
daily. Until E2 >250 pg/mL and/or the largest ovarian follicles 
reach 17–18 mm in diameter by ultrasound examination, the 
stimulation was followed by an human chorionic gonadotro-
pin (HCG) injection (subcutaneous ovitrelle 0.25 mg/d). The 
oocyte retrieval was performed 36 hours later.
Toxicity
Side effects and hematological toxicity were graded accord-
ing to the Common Terminology Criteria for Adverse Events 
version 4.03. Each side effect, documented by the physician, 
was scored once per patient at maximum during the course, 
and the highest grade of occurrence was scored.
Blood sampling and assay methods
During the monitoring phase of the COS, venous blood 
samples were drawn in a serum-separating tube with intervals 
of 1–4 days. Serum estradiol levels were analyzed by electro-
chemiluminescence immunoassay (Modular Analytics E 170 
Roche Diagnostics, Basel, Switzerland). All samples were 
analyzed by the accredited clinical laboratory of the LUMC.
Statistical analysis
For the primary endpoint, toxicity due to CT was compared 
between both groups using chi-square and logistic regres-
sion analysis. For the secondary endpoints, peak estradiol 
serum levels and distinct stimulation protocols were associ-
ated with grade III/IV toxicity in the COS group by using 
regression analysis. Univariate and multivariate odds ratios 
along with their 95% confidence intervals were estimated. 
All tests were 2-tailed, and P-values <0.05 were considered 
significant. All data were analyzed using Statistical Pack-
age for Social Sciences software™ 20.0 (IBM Corporation, 
Armonk, NY, USA).
Results
Patient characteristics
Eighteen patients received COS prior to neo (adjuvant) CT. 
Ten patients received a COS protocol with tamoxifen and 
GnRH antagonist, four patients a protocol with a GnRH 
antagonist alone, and four patients a protocol with a GnRH 
agonist alone. Eight patients in the COS group received 2 
subsequent cycles of COS, whereas 10 patients received 1 
cycle of COS. The control group (N=18) consisted of patients 
who received neo (adjuvant) TAC CT between 2009 and 2016 
and were between 18 and 40 years old. Patient characteristics 
between both groups were similar, except for a lower age 
in the COS group vs the control group (30.5 vs 35.2 years, 
P=0.005). Two patients did not receive all 6 cycles of TAC 
in the COS group. One patient switched after one TAC cycle 
due to neutropenic enterocolitis (typhlitis) to 3 3-weekly 
cycles AC followed by 9 weekly cycles of paclitaxel, and 1 
patient chose to stop after 4 cycles of TAC without a medi-
cal necessity to discontinue the CT. Patient characteristics 
at diagnosis are summarized in Table 1.
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Toxicity
The observed grade III/IV side effects were neutropenic fever, 
neutropenic enterocolitis, fatigue, and pneumonia. No dif-
ference were seen in grade III/IV side effects between both 
groups. The incidence of side effects that occurred in both 
groups is given in Table 2. In the COS group an increase in 
thrombopenia grade I/II was seen; 4 patients had a grade I and 
1 patient had a grade II thrombopenia. Grade I/II stomatitis 
and constipation occurrence was significantly lower in the 
COS group as compared to the control group (P=0.008 and 
P=0.006, respectively). These results remained significant in 
multivariate analysis when adjusting for age (P=0.018 and 
P=0.020, respectively). No grade V toxicity occurred during 
the CT in either group.
Estradiol levels and toxicity
In the COS group, no association was found between the peak 
estradiol levels and distinct stimulation protocols and grade 
III/IV side effects of CT. The mean peak estradiol serum levels 
in the protocol with tamoxifen was 8,046 pmol/L (N=10) and 
in the protocol without tamoxifen 5,717 pmol/L (N=8); the 
peak estradiol levels per protocol are given in Table 3. The 
peak estradiol levels were not significantly different (P=0.351).
Discussion
This study shows that COS prior to TAC CT is not associated 
with an increase or decrease in grade III/IV side effects in 
breast cancer patients treated with neo (adjuvant) TAC CT. 
To the best knowledge of the authors, this is the first study 
on effects of COS on CT -induced side effects.
COS for fertility preservation prior to TAC CT appears 
to be safe in terms of toxicity in breast cancer patients, as it 
Table 1 Patient characteristics
Characteristics OS (n=18) Control (n=18) P-value
Median age (range), years 35.2 (22–38) 30.5 (25–40) 0.005
T-classification 0.32
T1 10 (55.6%) 7 (38.8%)
T2–T4 8 (44.4%) 11 (61.1%)
N-classification 0.73
N0 12 (66.7%) 11 (61.1%)
N+ 6 (33.3%) 7 (38.9%)
HR status 0.49
ER and PR negative 6 (33.3%) 8 (42.1%)
ER and/or PR positive 12 (66.7%) 10 (58.8%)
HER-2 status 0.29
Negative 17 (94.4%) 15 (83.3%)
Positive 1 (5.6%) 3 (16.7%)
Radiotherapy before CT 0.49
No 12 (66.7%) 14 (77.8%)
Yes 6 (33.3%) 4 (22.2%)
Medication
Tamoxifen + GnRH 
antagonist
10 (55.6%)
GnRH agonist 4 (22.2%)
GnRH antagonist 4 (22.2%)
Number of cycles
1 10 (55.6%)
2 8 (44.4%)
Abbreviations: CT, chemotherapy; ER, estrogen receptor; GnRH, gonadotropin-
releasing hormone; HR, hormone receptor; OS, ovarian stimulation; PR, 
progesterone receptor.
Table 2 Grade I/II and grade III/IV toxicity during 6 cycles of TAC in both arms
Adverse event OS Control P-value OR (95% CI) P-value, OR (95% CI),  
multivariate
Any grade
Fatigue 13 14 0.700 0.74 (0.16–3.38)
Mucositis 5 13 0.008 0.15 (0.03–0.06) 0.018, 0.13 (0.03–0.70)
Neuropathy 5 7 0.480 0.60 (0.15–2.45)
Diarrhea 8 4 0.157 2.80 (0.66–11.9)
Nausea 12 13 0.717 0.77 (019–3.19)
Vomiting 7 5 0.362 1.66 (0.41–6.71)
Eye complaints 5 9 0.171 0.39 (0.10–1.54)
Constipation 7 15 0.006 0.13 (0.27–0.61) 0.020, 0.13 (0.022–0.721)
Anemia 11 13 0.480 0.60 (0.15–2.45)
Thrombopenia 5 0 NA NA
Leukopenia 7 4 0.278 2.23 (0.52–9.59)
Neutropenia 6 3 0.248 2.50 (0.52–12.1)
Grade III/IV
Total grade III/IV 6 5 0.717 1.30 (0.31–5.39)
Febrile neutropenia 5 2 0.206 3.08 (0.51–18.5)
Notes: All side effects were scored according CTCAE4.03. Each side effect was scored maximal once per patient during the course (the highest grade of occurrence was 
scored). The multivariate model has been adjusted for age.
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; NA, not applicable; OR, odds ratio; OS, ovarian stimulation; TAC, docetaxel, adriamycin, and 
cyclophosphamide.
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did not increase grade III/IV side effects. However, we found 
a significant increase in grade I/II thrombopenia in the COS 
group. Because thrombocytopenia grade II (<75.0×109/L 
blood platelets) might require delay and/or dose reduction 
of the CT, these results need to be validated in a larger study.
Interestingly, COS had a protective effect on mucositis and 
constipation. The protective effect of COS on occurrence of 
mucositis during CT treatment may be due to the hormonal 
alterations caused by COS. Analogously, estrogen treatment 
had a beneficial effect on recurrent aphthous mouth ulcers in 
premenopausal healthy women19 and on oral discomfort in 
postmenopausal women.20 Additionally, the estrogen recep-
tor has been detected in the oral mucosa.21,22 Thus, decrease 
in occurrence of mucositis in the COS group may be due to a 
transient increase of estradiol levels due to COS and its effects 
on the oral mucosa. The beneficial effect on constipation may 
be caused by the hormonal alternations as well. Researchers 
found a beneficial effect of estrogen on stool consistency 
and ease of passage in healthy postmenopausal women.23 
However, this effect might also be due to variable antiemetics 
protocols used in the different hospitals, as antiemetics can 
cause constipation.24
As an alternative for COS, ovarian tissue cryopreservation 
is an option for breast cancer patients under the age of 35 
years with CT resulting in >50% loss of ovarian reserve.25 
Although, it does not require COS and can be performed 
without delaying the start of CT, ovarian tissue cryopreserva-
tion requires surgery and is still in the experimental stage. 
The success rate for pregnancy has been estimated between 
11% and 30%;26 however, presumably, the success rate can-
not be accurately determined yet.27 Our study results support 
the usage of COS prior to CT because of the absence of a 
significant effect on grade III/IV side effects during CT. 
Moreover, patients with a mutation of BRCA1/2 might choose 
preimplantation genetic diagnosis, which requires COS and 
an in vitro fertilization procedure.28
It seems important to emphasize that the sample size 
of our study was small. Therefore, the results need to be 
validated in a larger cohort. Another limitation of our study 
was the significant difference in age between the COS and 
control group. We cannot rule out that this difference might 
be related to our results, although we used the same inclusion 
criteria for age in both groups. Moreover, in this retrospec-
tive study, the estradiol levels of the patients in the control 
group were unknown, and these levels may be valuable for 
the comparison between both groups in a future study.
Conclusion
In conclusion, COS prior to TAC CT is not associated with 
an increase in grade III/IV side effects. COS may increase 
grade I/II thrombocytopenia and may have a protective effect 
on mucositis and constipation.
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